Pulse lineResearch With Heart Logo

Associations of 1,5-Anhydroglucitol and 2-Hour Glucose with Major Clinical Outcomes in the Atherosclerosis Risk in Communities (ARIC) Study.

TitleAssociations of 1,5-Anhydroglucitol and 2-Hour Glucose with Major Clinical Outcomes in the Atherosclerosis Risk in Communities (ARIC) Study.
Publication TypeJournal Article
Year of Publication2020
AuthorsWarren B, Lee AK, Ballantyne CM, Hoogeveen RC, Pankow JS, Grams ME, Köttgen A
Secondary AuthorsSelvin E
JournalJ Appl Lab Med
Volume5
Issue6
Pagination1296-1306
Date Published2020 Nov 01
ISSN2576-9456
Abstract

BACKGROUND: 1,5-Anhydroglucitol (1,5-AG) is a novel biomarker of glycemic control proposed to monitor recent hyperglycemic excursions in persons with diabetes. The clinical utility of 1,5-AG outside of diagnosed diabetes is unclear, but it may identify people at high risk for diabetes and its complications. We compared associations of 1,5-AG with 2-h glucose for risk of major clinical complications.

RESEARCH DESIGN AND METHODS: We prospectively followed 6644 Atherosclerosis Risk in Communities (ARIC) Study participants without diagnosed diabetes for incident diagnosed diabetes, chronic kidney disease, cardiovascular disease, and all-cause mortality for ∼20 years. We assessed associations of 1,5-AG and 2-h glucose (modeled categorically and continuously with restricted cubic splines) with adverse outcomes using Cox models and evaluated improvement in risk discrimination using Harrell's c-statistic.

RESULTS: 1,5-AG

CONCLUSIONS: In this community-based population without diagnosed diabetes, low 1,5-AG was modestly associated with major clinical outcomes and did not outperform 2-h glucose.

DOI10.1093/jalm/jfaa066
Alternate JournalJ Appl Lab Med
PubMed ID32529222
PubMed Central IDPMC7648735
Grant ListK24 DK106414 / DK / NIDDK NIH HHS / United States
R01 DK089174 / DK / NIDDK NIH HHS / United States